In our study, we used LPS to generate the in vivo model, and overexpression of LINC00240 in the in vivo preeclampsia model inhibited the symptoms of preeclampsia including hypertension, proteinuria, and damages to liver and kidney, making LINC00240 a potential therapeutic target for preeclampsia. Here, LINC00240 is linked to hypertensive disorder.